Yahoo · Nov 3, 2026
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised
WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.
OP
NASDAQ · OPK
OPKO Health, Inc.
Healthcare · Medical - Diagnostics & Research
$1.72
Up+$0.05 (+2.91%)
Updated Nov 4, 2026, 11:49 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.06B
- P/E ratio
- -7.64
- Dividend yield
- 0.00%
- 52-week range
- $0.98 – $1.81
- Volume
- 4.16M
- Avg. volume
- 2.42M
Price performance · OPK
OPK price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
OPK closed at $1.72 after 21 trading sessions, up 17.81% for the selected period.
- Last close
- $1.72
- Period change
- +17.81%
- Period low
- $1.32
- Period high
- $1.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $1.75 | $1.81 | $1.71 | $1.72 | 4.16M |
| Nov 2, 2026 | $1.68 | $1.73 | $1.68 | $1.72 | 3.08M |
| Oct 30, 2026 | $1.66 | $1.69 | $1.64 | $1.66 | 2.15M |
| Oct 29, 2026 | $1.62 | $1.67 | $1.61 | $1.66 | 1.98M |
| Oct 28, 2026 | $1.60 | $1.655 | $1.59 | $1.62 | 2.55M |
| Oct 27, 2026 | $1.63 | $1.64 | $1.59 | $1.61 | 4.16M |
| Oct 26, 2026 | $1.65 | $1.67 | $1.63 | $1.63 | 1.92M |
| Oct 23, 2026 | $1.61 | $1.65 | $1.60 | $1.63 | 1.8M |
| Oct 22, 2026 | $1.60 | $1.67 | $1.58 | $1.63 | 2.2M |
| Oct 21, 2026 | $1.66 | $1.66 | $1.595 | $1.60 | 2.49M |
| Oct 20, 2026 | $1.63 | $1.73 | $1.62 | $1.66 | 4.35M |
| Oct 19, 2026 | $1.55 | $1.62 | $1.53 | $1.61 | 4.03M |
| Oct 16, 2026 | $1.73 | $1.77 | $1.50 | $1.53 | 12M |
| Oct 15, 2026 | $1.65 | $1.70 | $1.48 | $1.61 | 55.45M |
| Oct 14, 2026 | $1.31 | $1.37 | $1.30 | $1.37 | 1.64M |
| Oct 13, 2026 | $1.38 | $1.39 | $1.32 | $1.32 | 1.56M |
| Oct 12, 2026 | $1.377 | $1.39 | $1.36 | $1.38 | 1.01M |
| Oct 9, 2026 | $1.38 | $1.42 | $1.37 | $1.38 | 1.09M |
| Oct 8, 2026 | $1.37 | $1.3999 | $1.34 | $1.37 | 2.47M |
| Oct 7, 2026 | $1.42 | $1.43 | $1.375 | $1.39 | 2.22M |
| Oct 6, 2026 | $1.59 | $1.59 | $1.46 | $1.46 | 2.46M |
Latest OPK news
The latest Smart Investors Daily articles mentioning OPK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OPK research
Overview
Company profile and research snapshot.
Company profile
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | Piper Sandler | Overweight | — |
| Oct 16, 2026 | Barrington Research | Outperform | — |
| Apr 29, 2026 | Barrington Research | Market Perform | — |
| Mar 2, 2026 | Barrington Research | Outperform | — |
| Nov 20, 2025 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 3, 2026
OPKO Health (OPK) Stock Looks Pricey As Focus Turns To Its 58% Five Year Fall
OPKO Health has climbed in 2024 yet carries a much longer track record that includes a steep multi year decline, which puts a spotlight on whether the current share price lines up with the revenue story. With the stock trading at US$1.72, the key question is how that tag compares with what the business actually generates in sales. OPKO Health shareholders have seen the stock fall 58.4% over the past 5 years, so any reassessment of its worth now hinges heavily on what its revenue base can...
Yahoo · Oct 30, 2026
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
Yahoo · Oct 29, 2026
Reasons to Hold Hinge Health Stock in Your Portfolio for Now
HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
